We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Elevated Gene Expression Correlates with Prostate Cancer Severity

By LabMedica International staff writers
Posted on 10 Sep 2018
Elevated expression of the gene ANO7 has been shown to correlate with the severity and possible outcome of prostate cancer (PrCa).

Based on earlier studies showing that genetic signals at 2q37, the location of the prostate specific ANO7 gene were indicators of likelihood of developing prostate cancer, investigators at the University of Turku, Finland) focused on this gene as part of their effort to find germline biomarkers that could predict outcome of the disease.

To investigate, in detail, the associations between the ANO7 gene and PrCa risk and disease aggressiveness, ANO7 from castration resistant tumors was sequenced together with samples from unselected PrCa patients and unaffected males. More...
Two pathogenic variants were discovered and genotyped in 1769 patients and 1711 unaffected males.

Variant rs77559646 showed both risk and association with aggressive PrCa, while high ANO7 expression was independently linked to poor survival. ANO7 genotypes correlated with expression and biochemical relapse, suggesting that ANO7 was a potential PrCa susceptibility gene and that its elevated expression correlated with disease severity and outcome.

"We found that small genetic changes to the ANO7 gene increase a patient's risk of aggressive prostate cancer. One of the current biggest unmet needs in prostate cancer care is being able to diagnose aggressive cancers at an early stage. Genetic testing for ANO7 could help identify these patients sooner and may bring new opportunities for precision oncology in prostate cancer," said senior author Dr. Johanna Schleutker, professor of biomedicine of the University of Turku.

The study was published in the August 29, 2018, online edition of the International Journal of Cancer.

Related Links:
University of Turku


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.